Daiwa Securities Group Inc. - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 277 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2023. The put-call ratio across all filers is 0.28 and the average weighting 0.2%.

Quarter-by-quarter ownership
Daiwa Securities Group Inc. ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q2 2024$27
+8.0%
400
+10.2%
0.00%
Q1 2024$25
-10.7%
363
-7.9%
0.00%
Q4 2023$28
+55.6%
394
+14.2%
0.00%
Q3 2023$18
-18.2%
3450.0%0.00%
Q2 2023$22
+4.8%
345
-9.4%
0.00%
Q1 2023$21
+5.0%
3810.0%0.00%
Q4 2022$20
-99.9%
381
+8.2%
0.00%
Q3 2022$16,000
-20.0%
3520.0%0.00%
Q2 2022$20,000
+17.6%
352
+27.1%
0.00%
Q1 2022$17,000
+41.7%
277
+16.4%
0.00%
Q4 2021$12,000
+20.0%
238
-14.7%
0.00%
Q3 2021$10,000
+66.7%
279
+84.8%
0.00%
Q2 2021$6,000
+20.0%
1510.0%0.00%
Q1 2021$5,0000.0%1510.0%0.00%
Q4 2020$5,000
-44.4%
151
-58.5%
0.00%
Q3 2020$9,000
+50.0%
3640.0%0.00%
Q2 2020$6,0000.0%3640.0%0.00%
Q1 2020$6,000
-40.0%
364
+20.5%
0.00%
Q4 2019$10,000
+400.0%
3020.0%0.00%
Q3 2019$2,000
-50.0%
3020.0%0.00%
Q2 2019$4,0000.0%3020.0%0.00%
Q1 2019$4,000
+33.3%
3020.0%0.00%
Q4 2018$3,000
-57.1%
3020.0%0.00%
Q3 2018$7,000
+40.0%
3020.0%0.00%
Q2 2018$5,000
-16.7%
3020.0%0.00%
Q1 2018$6,0003020.00%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q1 2023
NameSharesValueWeighting ↓
DCF Advisers, LLC 375,000$15,308,0005.42%
SILVERARC CAPITAL MANAGEMENT, LLC 113,258$4,623,0002.06%
Tri Locum Partners LP 150,783$6,155,0002.02%
COOPER/HAIMS ADVISORS, LLC 61,116$2,495,0001.64%
Vantage Consulting Group Inc 226,670$9,252,0001.61%
Nicholas Investment Partners, LP 598,261$24,421,0001.53%
Bellevue Group AG 3,609,919$147,357,0001.44%
GENERAL AMERICAN INVESTORS CO INC 350,804$14,320,0001.20%
Rhenman & Partners Asset Management AB 429,728$17,541,0001.19%
WASATCH ADVISORS LP 6,506,789$265,607,0001.08%
View complete list of INTRA CELLULAR THERAPIES INC shareholders